Characteristics of 10-year survivors of high-grade serous ovarian carcinoma

• Published in: Gynecologic oncology Vol. 141; no. 2; pp. 260 - 263
• Main Authors: Dao, Fanny, Schlappe, Brooke A, Tseng, Jill, Lester, Jenny, Nick, Alpa M, Lutgendorf, Susan K, McMeekin, Scott, Coleman, Robert L, Moore, Kathleen N, Karlan, Beth Y, Sood, Anil K, Levine, Douglas A
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.05.2016
• Subjects: Adult; Aged; Aged, 80 and over; Cystadenocarcinoma, Serous - genetics; Cystadenocarcinoma, Serous - mortality; Cystadenocarcinoma, Serous - pathology; Female; Genes, BRCA1; Genes, BRCA2; Germ-Line Mutation; Hematology, Oncology and Palliative Medicine; Humans; Long-term survival; Middle Aged; Neoadjuvant chemotherapy; Neoplasm Grading; Obstetrics and Gynecology; Outcome; Ovarian cancer; Ovarian Neoplasms - genetics; Ovarian Neoplasms - mortality; Ovarian Neoplasms - pathology; Ovarian Neoplasms - therapy; Pilot Projects; Surgical cytoreduction; Survival; Survivors - statistics & numerical data; Treatment Outcome; United States - epidemiology; Neoadjuvant chemotherapy; Long-term survival; Surgical cytoreduction; Survival; Outcome; Ovarian cancer
• ISSN: 0090-8258; 1095-6859
• DOI: 10.1016/j.ygyno.2016.03.010

Abstract Objective High-grade serous carcinoma (HGSC) generally presents at an advanced stage with poor long-term (LT) survival. Here we describe clinical features found in women surviving HGSC for ten or more years. Methods A multi-center research consortium was established between five participating academic centers. Patient selection criteria included high-grade serous ovarian, fallopian tube, or peritoneal carcinoma with at least ten years of follow up. Non-serous, borderline tumors and low-grade serous subtypes were excluded. Results The 203 identified LT ten-year survivors with HGSC were diagnosed at a median age of 57 years (range 37–84 years). The majority of patients had stage IIIC (72.4%) disease at presentation. Of those who underwent primary cytoreductive surgery, optimal cytoreduction was achieved in 143 (85.6%) patients. After a median follow up of 144 months, 88 (46.8%) patients did not develop recurrent disease after initial treatment. Unexpected findings from this survey of LT survivors includes 14% of patients having had suboptimal cytoreduction, 11% of patients having an initial platinum free interval of < 12 months, and nearly 53% of patients having recurrent disease, yet still surviving more than ten years after diagnosis. Conclusions LT survivors of HGSC of the ovary generally have favorable clinical features including optimal surgical cytoreduction and primary platinum sensitive disease. The majority of patients will develop recurrent disease, however many remained disease free for more than 10 years. Future work will compare the clinical features of this unusual cohort of LT survivors with the characteristics of HGSC patients having less favorable outcomes.